Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06189404 · ClinicalTrials.gov registry record · Phase 1
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
A Phase 1 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06189404 is a Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 24 participants.
The verdict
NCT06189404, a Phase 1 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A phase 1, open-label, drug-drug interaction study to evaluate the effect of multiple doses of tigulixostat on the pharmacokinetics of single-dose theophylline in healthy adult volunteers.
Interventions
- DRUG Theophylline
- DRUG Tigulixostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06189404
The ClinicalTrials.gov registry entry for NCT06189404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Theophylline is the first listed.
NCT06189404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06189404 about?
NCT06189404 is a clinical study titled "Effect of Tigulixostat on the Pharmacokinetics of Theophylline". A phase 1, open-label, drug-drug interaction study to evaluate the effect of multiple doses of tigulixostat on the pharmacokinetics of single-dose theophylline in healthy adult volunteers.
What is the current status of trial NCT06189404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-10-31. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT06189404?
The interventions under investigation include: Theophylline (DRUG), Tigulixostat (DRUG).
Who is sponsoring clinical trial NCT06189404?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.